SLN
NASDAQ HealthcareSilence Therapeutics Plc - American Depository Share
Biotechnology
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
๐ Market Data
| Price | $10.92 |
|---|---|
| Volume | 567,549 |
| Market Cap | 515.80M |
| Beta | 1.380 |
| RSI (14-Day) | 59.1 |
| 200-Day MA | $6.52 |
| 50-Day MA | $7.78 |
| 52-Week High | $11.06 |
| 52-Week Low | $4.19 |
| Forward P/E | -28.00 |
| Price / Book | 10.44 |
๐ฏ Investment Strategy Scores
SLN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (70/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ช Falling Knife (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SLN in your text
Paste any article, transcript, or post โ the tool will extract SLN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.